At the beginning of twenty century Alois Alzheimer described the pathology that now bears his name (Alzheimer, 1907). Over a hundred years later, Alzheimer’s disease (AD) is the most common cause of dementia in developed countries. Here eighteen million people are currently affected and the number of patients is expected to increase dramatically with the ongoing increase in the elderly population (Fotuhi et al., 2009, Mount & Downton, 2006). Because no suitable biomarkers are available, the diagnosis of AD remains inconclusive until postmortem pathological analysis, and physicians rely on behavioral manifestations to differentiate between AD and other conditions. For this reason firm diagnosis is generally only made at later stages of the disorder when treatment is purely palliative. These features make AD a social and economic challenge in developed countries (Wimo et al., 2010).
Clinically, AD is characterized by progressive loss of cognitive functions with specific deficits in episodic memory. Clinical diagnosis of is generally only made when cognitive deficits are sufficiently severe to cause dependent status of the patient (Nestor et al., 2004). Pathological analyses of AD brain have described two distinct types of proteinopathy in the frontal and temporal lobes involving the limbic system and the basal forebrain. The first type comprises aggregates of beta-amyloid peptide (Aβ) – a specific fragment of the amyloid precursor protein (APP), a plasma membrane protein. These aggregates accumulate in the extracellular space and give rise to senile plaques (SPs). SPs cause synaptotoxicity, neurotoxicity, oxidative stress and hypoxia (Peers et al., 2009, Selkoe, 2001, 2008). The second proteinopathy occurs in the cytosol. Hyperphosphorylation and abnormal aggregation of the microtubule-associated protein tau leads to the intracellular formation of neurofibrillary tangles (NFTs) which cause cytoskeleton destabilization and eventually cell death (Hernandez & Avila, 2008, Selkoe, 2001).
It has been widely reported that olfactory loss (anosmia and hyposmia) takes place in the early stages of AD, and before any detectable cognitive deficits are present. Interestingly, AD pathology extends throughout the limbic system and the basal forebrain, including the olfactory system (Braak & Braak, 1991). The human olfactory system includes peripheral sensory neurons in the olfactory epithelium; these send their axons across the cribriform plate of the etmoides bone to the olfactory bulbs. In the glomerular layer of the olfactory bulbs their axons synapse with dendrites of the mitral and tufted cells which in turn project to the main olfactory cortex in the basal forebrain. The human olfactory system constitutes complex circuit connections including primary and secondary cortical areas that are connected, as represented schematically in Figure 1.
The progression of AD pathology has been divided into six stages according to the extent of NFT accumulation. Accumulation is first detected in the entorhinal cortex and hippocampus of the limbic system; this extends into the basal forebrain including the olfactory system (Braak & Braak, 1991, Price et al., 1991, Van Hoesen et al., 1991), and from the rostral entorhinal cortex, periamygdaloid cortex, and piriform cortex, to the olfactory tubercle, anterior olfactory nucleus and olfactory bulbs (Fig. 1). Tau pathology has also been described in the olfactory epithelium (Lee et al., 1993). Olfaction is affected in many psychiatric disorders in addition to AD, including Parkinson’s disease, Huntington’s disease, schizophrenia, senile dementia of Lewy body type, and depression (Atanasova et al., 2008,Kovacs, 2004). It has been widely reported over the past 25 years that olfaction is impaired in AD (Djordjevic et al., 2008, Doty et al., 1987, Mesholam et al., 1998, Murphy, 1999, Murphy et al., 1990, Serby et al., 1985, 1991), and olfaction has become a priority area in the search for biomarkers to establish an early diagnosis of AD and to facilitate early therapeutic intervention (Doty, 2003,Hampel et al., 2010,Hawkes, 2009,Wilson et al., 2009). It has been proposed that the early involvement of the entorhinal cortex and the hippocampus, regions that are tightly related to memory deficiencies (Nagy et al., 1996), could be also the cause of olfactory deficits (Wilson et al., 2007). However, other authors suggest that alternative olfactory areas, for example the posterior part of the piriform cortex, are the specific cause of olfactory deficiencies (Li et al., 2010). Nevertheless, the neural basis underlying hyposmia in the AD brain remain uncertain.
2. Materials and methods
We have studied the olfactory system in 19 AD cases and 7 age-matched controls from the Banc de Teixits Neurològics, Universitat de Barcelona-Hospital Clínic and the Banco de Tejidos/Fundación para Investigaciones Neurológicas, Universidad Complutense de Madrid. Mean ages (± standard derivation) in AD and controls were 77.68 ± 9.01 yr and 74.57 ± 4.47 yr, respectively.Tissue samples were fixed by immersion in paraformaldehyde 4% for one month at least. Then, samples were cryoprotected in 30% w/v sucrose and 50µm coronal sections were obtained using a sliding freezing microtome.
To study the early stages of disease development we employed a double transgenic mouse model of Alzheimer disease (
In order to delimit areas of interest sections were stained by Nissl technique (Fig. 2A). Primaryantibodies used for immunodetection were mouse anti-tau (tau 46,1:800, Cell Signaling Technology, Beverly, MA, USA), rabbit anti-Aβ(1:250, Cell Signaling Technology), and goat anti-somatostatin D-20(1:1000, Santa Cruz Biotechnology, Santa Cruz, CA, USA). Secondaryantibodies were either biotinylated (anti-goat IgG, 1:2000, VectorLaboratories, Burlingame, CA, USA) or fluorescent-labeled (1:200,alexas 488 donkey anti-mouse, 568 donkey anti-rabbit, and 350donkey anti-goat; Molecular Probes, Invitrogen, Carlsbad, CA, USA).
For quantification, somatostatin-positive cells were charted with an X-Y recording system (AccuStage, Minnesota Datametrics, MN, USA). Colocalization levels were measured by confocal microscopy using LSM 710 Zeiss confocalmicroscope (Carl Zeiss MicroImaging, Barcelona, Spain).Intensities of each fluorochrome were analyzed using the profiletool of the ZEN software (Zeiss).
One-way ANOVA followed by
3. Interneurons in the olfactory system
Interneurons constitute 20–30% of the neuronal population of the cerebral cortex and possess distinct morphological, electrophysiological and neurochemical characteristics (Ascoli et al., 2008, DeFelipe, 1997, Markram et al., 2004). Two primary features are common to all interneuron subpopulations. First, these cells are predominantly inhibitory interneurons which express γ-aminobutyric acid (GABA), an inhibitory neurotransmitter; and, second, their neuronal connectivity is predominantly restricted to the local region of the brain (DeFelipe & Farinas, 1992, Kawaguchi & Kondo, 2002).
Interneurons are tightly related to the pathoetiology of AD, and many reports have described the involvement of interneuron subpopulations in AD neuropathology (Attems et al., 2008, Brady & Mufson, 1997, Geula et al., 2003, Saiz-Sanchez et al., 2010, Solodkin et al., 1996, Supnet & Bezprozvanny). It was recently reported that numbers of interneurons in the entorhinal cortex and hippocampus are significantly reduced in early AD stages (Koliatsos et al., 2006). Interneurons regulate synaptic signaling by pyramidal neurons and the loss of this regulation could produce deficits in learning and memory (Palop et al., 2003, Wallenstein & Hasselmo, 1997). Moreover, disregulation of olfactory information-processing due to loss of interneurons could underlie the hyposmia described in the early stages of the disease. This review focuses on four major types of interneurons based on their importance to AD etiology and brain calcium homeostasis: respectively cells expressing somatostatin, calbindin, calretinin or parvalbumin. We also discuss the distribution of different types of interneurons and their involvement with tau and β-amyloid pathology as revealed by confocal microscopy.
The neuropeptide somatostatin is implicated in diverse functions in the central nervous system (Epelbaum, 1986,Viollet et al., 2008). Somatostatin is expressed in all olfactory areas. Recently, somatostatin has been linked with AD etiology because it is reported to act as a positive regulator of neprilysin, an enzyme which catalyzes the degradation of β-amyloid peptide (Saito et al., 2005). Somatostatin levels decline with aging (Lu et al., 2004) and are further reduced in AD (Davies et al., 1980). It has been proposed that the decline in somatostatin levels with age could explain the age-dependency of AD onset because reduced somatostatin would be expected to lead to downregulation of neprilysin activity, thereby predisposing to the accumulation of β-amyloid peptide (Hama & Saido, 2005).
Confocal microscopy of the olfactory system in AD brain has revealed that somatostatin is selectively reduced, by up to 50%, in olfactory areas such as anterior olfactory nucleus (AON). Moreover, the deficiency in somatostatin was predominantly associated with β-amyloid pathology rather than tau pathology (Figs 2,3). These findings are in agreement with the theory of Hama & Saido that there is a tight relationship between somatostatin and β-amyloid. The AON is an important relay in olfactory information processing (Price, 1990). Two distinct portions of the AON can be distinguished in the basal forebrain – the medial AON and the lateral AON divided by the olfactory tract (Fig. 2A). The AON is an early site for the accumulation of tau protein (Fig. 2B) (Price et al., 1991) and is also targeted for β-amyloid deposition (Fig. 2C). Somatostatin-expressing cells in the AON possess typical bipolar interneuron morphology. Confocal analyses show that most somatostatin-cells expressing are not associated with tau pathology (Figs 2E,Fand 3), and somatostatin-expressing cells are most commonly associated with β-amyloid or with β-amyloid plus tau (Figs 2F and 3).
All olfactory areas showed a marked accumulation of β-amyloid deposits, but the extent of accumulation in olfactory tubercle (Tu) was less than in other areas (Fig. 5 A–D). The greatest reduction in cells expressing somatostatin was seen in the external plexiform layer (EPL) (Fig. 5E,F) of the olfactory bulb, the piriform cortex (Pir) and the entorhinal cortex (Ent). In addition, the olfactory tubercle (Tu) and anterior olfactory nucleus (AON) both showed
significant reductions in levels of somatostatin-positive cells. Different forms of colocalization were observed,including isolated cells (Fig. 5G), fibers and cell debris (Fig. 5H,I). Colocalization increased with age and was greater in caudal olfactory areas than in rostral areas. No colocalization was found in the external plexiform layer of the olfactory bulb where β-amyloid pathology was restricted to the granule cell layer (Fig. 5A,D) and was largely absent from the EPL.
3.2. Calcium-binding proteins
Calcium is an intracellular second messenger that mediates physiological responses of neurons to chemical and electrical stimulation. In AD defective calcium homeostasis is thought to cause aberrant cellular metabolism and promote cell death (Heizmann & Braun, 1992,Mattson, 2007). Calcium has been related to changes in learning (Foster, 2007,Palop et al., 2003) and altered calcium regulation has been reported in AD brains before any cognitive deficits become apparent (Bezprozvanny & Mattson, 2008).
Our analysis focused on three interneuron subpopulations expressing three different calcium-binding proteins (CaBP): calbindin, calretinin and parvalbumin. All three proteins are expressed in the olfactory system, but with different distributions.
In AD brain, calbindin D-28k is expressed widely throughout the olfactory system and is particularly abundant in key structures of olfactory processing such as the AON (Fig. 6A,B) and the piriform cortex (Fig. 6C). Especially evident is the pathological involvement of calbindin 28-Dk in the piriform cortex (Fig. 6C) where aberrant morphologies of calbindin-expressing dystrophic neuritis can be observed (Fig. 6D). Although calbindin-positive cells in the human olfactory system show some involvement with β-amyloid pathology, there was a stronger association with tau pathology (Fig. 6E,F).
Whereas calbindin D-28k is firmly associated with AD neuropathology, the involvement of calretinin in AD is more controversial (Brion & Resibois, 1994,Fonseca & Soriano, 1995,Hof et al., 1993,Sampson et al., 1997). Some authors propose that calretinin-positive cells are resistant to disease progression as a result of its capacity to buffer intracellular calcium levels. Furthermore, the potential role of calretinin in the neural basis of hyposmia remains unclear. We have studied the distribution of calretinin distribution in the human olfactory system and its involvement by tau and β-amyloid pathology.
Microscopy observations revealed that calretinin is present throughout the olfactory system. AD brain expression levels were found to be markedly reduced in olfactory areas such as AON (Fig. 7B) and Pir (Fig. 7C) relative to control brain (Fig. 7D). As with calbindin-expressing cells, calretinin-positive cells showed aberrant morphologies. In addition, these cells showed preferential involvement of tau pathology. In the olfactory bulb calretinin was found to be expressed in the periglomerular cells (Fig. 7A). It is interesting to note that sensory neurons from the olfactory epithelium send their axons to glomeruli in the olfactory bulb where they make synapses with dendrites of mitral cells. These synapses are regulated by periglomerular cells (Fig. 1). Involvement of periglomerular cells could therefore lead to disregulation of olfactory perception at the early stages of the disease.
The third subclass of interneurons studied were those expressing parvalbumin. As with calretinin, the involvement of parvalbumin in AD is controversial. On the one hand it has been reported that there is an up to 60% decrease in the parvalbumin-positive cell population in AD hippocampus (Brady & Mufson, 1997) and entorhinal cortex (Mikkonen et al., 1999,Solodkin et al., 1996). On the other, no association was found between parvalbumin-positive cells and tau pathology in AD (Sampson et al., 1997).
In the human brain parvalbumin-expressing cells were present throughout the olfactory system and were particularly abundant in caudal olfactory areas such as piriform cortex (Fig. 8) and entorhinal cortex. In contrast to cells expressing calbindin- and calretinin, parvalbumin-positive cells showed physiological morphology, even at advanced stages of disease (Fig. 8A,B). Confocal images showed that parvalbumin-positive cells were predominantly associated with tau pathology (Fig. 8C); there was less evidence of involvement with β-amyloid pathology. As with calbindin- and calretinin-expressing cells, tau/NFT was the predominantly neuropathology associated with these calcium-binding proteins.
In the present report we have studied the involvement of interneuron populations in the human olfactory system with AD neuropathology as revealed by two different disease markers: tau protein and β-amyloid peptide. Somatostatin-expressing interneurons in the olfactory system were preferentially associated with β-amyloid pathology in both AD brain and in
The four subpopulations of interneurons were not randomly distributed within the olfactory system. Somatostatin-expressing cells were present in the olfactory bulb but were restricted to the external plexiform layer (EPL) (Fig. 5). Somatostatin was also present in other olfactory areas, particularly in the anterior olfactory nucleus (AON). Calbindin-expressing cells were present in the olfactory system, and were particularly abundant in the AON. Calretinin-positivity constitutes a specific marker for periglomerular cells which regulate the first relay of olfactory information from the olfactory epithelium to the olfactory bulbs (Fig. 1). Calretinin-expressing cells were also abundant in the piriform cortex (Pir) and the entorhinal cortex (Ent). Parvalbumin-positive cells were more abundant in the more caudal areas studied (Pir and Ent) and were only sparsely distributed in rostral olfactory areas.
The wide presence of these interneuron populations in olfactory structures and the severe and early involvement of these regions in AD neuropathology has focused attention on the role of these cells in the pathoetiology of AD. Generalized involvement of these cells and loss of interneuron populations and/or disregulation of their primary projection cellscould underlie the olfactory deficits of AD patients. Loss of inhibitory regulation by γ-aminobutyric acid (GABA) could lead to altered firing patterns of projection neurons.
The olfactory system encompasses complex interconnections between several cortical areas (Fig. 1). Although it remains unknown whether dysfunction of specific interneuron populations in any given area could cause the olfaction deficits seen in AD, we report that there was selective association between different types of interneuron and AD neuropathology, as revealed by the two pathological markers employed in this study. However, it is not yet possible to relate these changes with specific olfaction deficits such as preferential or general anosmia, hyposmia or dysosmia. The specific contribution of each area in olfactory processing and how they are differentially affected during AD will need to be resolved before a specific olfactory test can be devised that could permit early diagnosis of AD.
The authors thank the Banc de Teixits Neurològics, Universitat de Barcelona-Hospital Clínic and the Banco de Tejidos/Fundación para Investigaciones Neurológicas, Universidad Complutense de Madrid, for providing the human brain samples. The authors also wish to thank the laboratory of Dr. Calvo for genotyping transgenic mice. This work was supported by the autonomous government of Castilla-La Macha (Project Nº PEIC11-0045-4490) and by the Spanish Science and Innovation Ministry (Project BFU2010-15729).
Ascoli G. A. Alonso-Nanclares L. Anderson S. A. Barrionuevo G. Benavides-Piccione R. Burkhalter A. Buzsaki G. Cauli B. Defelipe J. Fairen A. Feldmeyer D. Fishell G. Fregnac Y. Freund T. F. Gardner D. Gardner E. P. Goldberg J. H. Helmstaedter M. Hestrin S. Karube F. Kisvarday Z. F. Lambolez B. Lewis D. A. Marin O. Markram H. Munoz A. Packer A. Petersen C. C. Rockland K. S. Rossier J. Rudy B. Somogyi P. Staiger J. F. Tamas G. Thomson A. M. Toledo-Rodriguez M. Wang Y. West D. C. Yuste R. 2008 Petilla terminology: nomenclature of features of GABAergic interneurons of the cerebral cortex, 9 7July 2008), 557 568 1471-0048
Atanasova B. Graux J. El Hage W. Hommet C. Camus V. Belzung C. 2008 Olfaction: a potential cognitive marker of psychiatric disorders, 32 7September 2008), 1315 1325 0149-7634
Attems J. Preusser M. Grosinger-Quass M. Wagner L. Lintner F. Jellinger K. 2008 Calcium-binding protein secretagogin-expressing neurones in the human hippocampus are largely resistant to neurodegeneration in Alzheimer’s disease, 34 1February 2008), 23 32 0305-1846
Bezprozvanny I. Mattson M. P. 2008 Neuronal calcium mishandling and the pathogenesis of Alzheimer’s disease. , 31 9September 2008), 454 463 0166-2236
Braak H. Braak E. 1991 Neuropathological stageing of Alzheimer-related changes., 82 4 239 259 0001-6322
Brady D. R. Mufson E. J. 1997Parvalbumin-immunoreactive neurons in the hippocampal formation of Alzheimer’s diseased brain. Neuroscience, 80 4October 1997), 1113 1125 0306-4522
Brion J. P. Resibois A. 1994 A subset of calretinin-positive neurons are abnormal in Alzheimer’s disease., 88 1 33 43 0001-6322
Davies P. Katzman R. Terry R. D. 1980 Reduced somatostatin-like immunoreactivity in cerebral cortex from cases of Alzheimer disease and Alzheimer senile dementa. 288 5788November 1980), 279 280 0028-0836
De Felipe J. 1997Types of neurons, synaptic connections and chemical characteristics of cells immunoreactive for calbindin-D28K, parvalbumin and calretinin in the neocortex. , 14 1December 1997), 1 19 0891-0618
De Felipe J. Farinas I. 1992 The pyramidal neuron of the cerebral cortex: morphological and chemical characteristics of the synaptic inputs., 39 6December 1992), 563 607 0301-0082
Djordjevic J. Jones-Gotman M. De Sousa K. Chertkow H. 2008 Olfaction in patients with mild cognitive impairment and Alzheimer’s disease, 29 5May 2008), 693 706 1558-1497
Doty R. L. 2003Handbook of olfaction and gustation. Doty RL, editor; 2003.
Doty R. L. Reyes P. F. Gregor T. 1987 Presence of both odor identification and detection deficits in Alzheimer’s disease., 18 5May 1987), 597 600 0361-9230
Epelbaum J. 1986 Somatostatin in the central nervous system: physiology and pathological modifications., 27 1 63 100 0301-0082
Ferrer I. Tunon T. Serrano M. T. Casas R. Alcantara S. Zujar M. J. Rivera R. M. 1993Calbindin D-28k and parvalbumin immunoreactivity in the frontal cortex in patients with frontal lobe dementia of non-Alzheimer type associated with amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry, 56 3March 1993), 257 261 0022-3050
Fonseca M. Soriano E. 1995 Calretinin-immunoreactive neurons in the normal human temporal cortex and in Alzheimer’s disease, 691 1-2September 1995), 83 91 0006-8993
Foster T. C. 2007Calcium homeostasis and modulation of synaptic plasticity in the aged brain. Aging Cell, 6 3June 2007), 319 325 1474-9718
Fotuhi M. Hachinski V. Whitehouse P. J. 2009 Changing perspectives regarding late-life dementia, 5 12December 2009), 649 658 1759-4766
Geula C. Bu J. Nagykery N. Scinto L. F. Chan J. Joseph J. Parker R. Wu C. K. 2003 Loss of calbindin-D28k from aging human cholinergic basal forebrain: relation to neuronal loss., 455 2January 2003), 249 259 0021-9967
Hama E. Saido T. C. 2005 Etiology of sporadic Alzheimer’s disease: somatostatin, neprilysin, and amyloid beta peptide., 65 3 498 500 0306-9877
Hampel H. Frank R. Broich K. Teipel S. J. Katz R. G. Hardy J. Herholz K. Bokde A. L. Jessen F. Hoessler Y. C. Sanhai W. R. Zetterberg H. Woodcock J. Blennow K. 2010 Biomarkers for Alzheimer’s disease: academic, industry and regulatory perspectives., 9 7July 2010), 560 574 1474-1784
The Neurology of Olfaction: Cambridge University Press,Cambridge; Hawkes C. H. Doty R. L. 2009
Heizmann C. W. Braun K. 1992Changes in Ca(2+)-binding proteins in human neurodegenerative disorders. Trends Neurosci, 15 7July 1992), 259 264 0166-2236
Hernandez F. Avila J. 2008 Tau aggregates and tau pathology., 14 4August 2008), 449 452 1387-2877
Hof P. R. Nimchinsky E. A. Celio M. R. Bouras C. Morrison J. H. 1993 Calretinin-immunoreactive neocortical interneurons are unaffected in Alzheimer’s disease., 152 1-2April 1993), 145 148 0304-3940
Iacopino A. M. Christakos S. 1990 Specific reduction of calcium-binding protein (28-kilodalton calbindin-D) gene expression in aging and neurodegenerative diseases., 87 11January 1990), 4078 4082 0027-8424
Ichimiya Y. Emson P. C. Mountjoy C. Q. Lawson D. E. Heizmann C. W. 1988 Loss of calbindin-28K immunoreactive neurones from the cortex in Alzheimer-type dementia., 475 1December 1988), 156 159 0006-8993
Kawaguchi Y. Kondo S. 2002Parvalbumin, somatostatin and cholecystokinin as chemical markers for specific GABAergic interneuron types in the rat frontal cortex. , 31 3-5March-June 2002), 277 287 0300-4864
Koliatsos V. E. Kecojevic A. Troncoso J. C. Gastard M. C. Bennett D. A. Schneider J. A. 2006 Early involvement of small inhibitory cortical interneurons in Alzheimer’s disease, 112 2August 2006), 147 162 0001-6322
Kovacs T. 2004 Mechanisms of olfactory dysfunction in aging and neurodegenerative disorders., 3 2April 2004), 215 232 1568-1637
Lee J. H. Goedert M. Hill W. D. Lee V. M. Trojanowski J. Q. 1993 Tau proteins are abnormally expressed in olfactory epithelium of Alzheimer patients and developmentally regulated in human fetal spinal cord, 121 1May 1993), 93 105 0014-4886
Li W. Howard J. D. Gottfried J. A. 2010Disruption of odour quality coding in piriform cortex mediates olfactory deficits in Alzheimer’s disease. Brain, 133 9August 2010), 2714 2726 1460-2156
Lu T. Pan Y. Kao S. Y. Li C. Kohane I. Chan J. Yankner B. A. 2004Gene regulation and DNA damage in the ageing human brain. Nature, 429 6994June 2004), 883 891 1476-4687
Markram H. Toledo-Rodriguez M. Wang Y. Gupta A. Silberberg G. Wu C. 2004 Interneurons of the neocortical inhibitory system, 5 10October 2004), 793 807 0147-1003X
Mattson M. P. 2007Calcium and neurodegeneration. Aging Cell, 6 3June 2007), 337 350 1474-9718
Mesholam R. I. Moberg P. J. Mahr R. N. Doty R. L. 1998Olfaction in neurodegenerative disease: a meta-analysis of olfactory functioning in Alzheimer’s and Parkinson’s diseases. Arch Neurol, 55 1January 1998), 84 90 0003-9942
Mikkonen M. Alafuzoff I. Tapiola T. Soininen H. Miettinen R. 1999 Subfield- and layer-specific changes in parvalbumin, calretinin and calbindin-D28K immunoreactivity in the entorhinal cortex in Alzheimer’s disease. 92 2 515 532 0306-4522
Mount C. Downton C. 2006Alzheimer disease: progress or profit? , 12 7 780 784 1078-8956
Murphy C. 1999Loss of olfactory function in dementing disease. , 66 2April 1999), 177 182 0031-9384
Murphy C. MM Gilmore Seery. C. S. Salmon D. P. Lasker B. R. 1990Olfactory thresholds are associated with degree of dementia in Alzheimer’s disease. , 11 4July-August 1990), 465 469 0197-4580
Nagy Z. Jobst K. A. Esiri M. M. Morris J. H. King E. M. Mac Donald. B. Litchfield S. Barnetson L. Smith A. D. 1996Hippocampal pathology reflects memory deficit and brain imaging measurements in Alzheimer’s disease: clinicopathologic correlations using three sets of pathologic diagnostic criteria. Dementia, 7 2March-April 1996), 76 81 1013-7424
Nestor P. J. Scheltens P. Hodges J. R. 2004Advances in the early detection of Alzheimer’s disease. , 10Suppl, No. (July 2004), S34 S41 1078-8956
Palop J. J. Jones B. Kekonius L. Chin J. Yu G. Q. Raber J. Masliah E. Mucke L. 2003Neuronal depletion of calcium-dependent proteins in the dentate gyrus is tightly linked to Alzheimer’s disease-related cognitive deficits. , 100 16August 2003), 9572 9577 0027-8424
Peers C. Dallas M. L. Boycott H. E. Scragg J. L. Pearson H. A. Boyle J. P. 2009Hypoxia and neurodegeneration. , 1177No. (October 2009), 169 177 1749-6632
Price J. L. 1990Olfactory System. In: Paxinos G, editor. The Human Nervous System. San Diego: Academic Press; 1990. 979 998
Price J. L. Davis P. B. Morris J. C. White D. L. 1991The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer’s disease. Neurobiol Aging, 12 4July-August 1991), 295 312 0197-4580
Saito T. Iwata N. Tsubuki S. Takaki Y. Takano J. Huang S. M. Suemoto T. Higuchi M. Saido T. C. 2005Somatostatin regulates brain amyloid beta peptide Abeta42 through modulation of proteolytic degradation. , 11 4April 2005), 434 439 1078-8956
Saiz-Sanchez D. Ubeda-Banon I. de la Rosa-Prieto C. Argandona-Palacios L. Garcia-Munozguren S. Insausti R. Martinez-Marcos A. 2010Somatostatin, tau, and beta-amyloid within the anterior olfactory nucleus in Alzheimer disease. , 223 2June 2010), 347 350 1090-2430
Sampson V. L. Morrison J. H. Vickers J. C. 1997The cellular basis for the relative resistance of parvalbumin and calretinin immunoreactive neocortical neurons to the pathology of Alzheimer’s disease. Exp Neurol, 145 1May 1997), 295 302 0014-4886
Selkoe D. J. 2001Alzheimer’s disease: genes, proteins, and therapy. Physiol Rev, 81 2April 2001), 741 766 0031-9333
Selkoe D. J. 2008Biochemistry and Molecular Biology of Amyloid beta-Protein and the Mechanism of Alzheimer’s Disease. Handb Clin Neurol, 89No. 245 260 0072-9752
Serby M. Corwin J. Novatt A. Conrad P. Rotrosen J. 1985Olfaction in dementia. , 48 8September 1985), 848 849 0022-3050
Serby M. Larson P. Kalkstein D. 1991The nature and course of olfactory deficits in Alzheimer’s disease. , 148 3March 1991), 357 360 0000-2953X
Solodkin A. Veldhuizen S. D. Van Hoesen G. W. 1996Contingent vulnerability of entorhinal parvalbumin-containing neurons in Alzheimer’s disease. , 16 10May 1996), 3311 3321 0270-6474
Supnet C. Bezprozvanny I. 2010The dysregulation of intracellular calcium in Alzheimer disease. , 47 2February 2010) 183 189 1532-1991
Van Hoesen G. W. Hyman B. T. Damasio A. R. 1991Entorhinal cortex pathology in Alzheimer’s disease. Hippocampus, 1 1January 1991), 1 8 1050-9631
Viollet C. Lepousez G. Loudes C. Videau C. Simon A. Epelbaum J. 2008Somatostatinergic systems in brain: Networks and functions. , 286 1-2May 2008), 75 87 0303-7207
Wallenstein G. V. Hasselmo M. E. 1997GABAergic modulation of hippocampal population activity: sequence learning, place field development, and the phase precession effect. J Neurophysiol, 78 1July 1997), 393 408 0022-3077
Wilson R. S. Arnold S. E. Schneider J. A. Boyle P. A. Buchman A. S. Bennett D. A. 2009Olfactory impairment in presymptomatic Alzheimer’s disease. Ann N Y Acad Sci, 1170No. (July 2009), 730 735 1749-6632
Wilson R. S. Arnold S. E. Schneider J. A. Tang Y. Bennett D. A. 2007The relationship between cerebral Alzheimer’s disease pathology and odour identification in old age. , 78 1January 2007), 30 35 0146-8330X
Wimo A. Winblad B. Jonsson L. 2010The worldwide societal costs of dementia: Estimates for 2009. , 6 2March 2010), 98 103 1552-5279